 |
 |
|
1 April 1998 | Volume 128 Issue 7 | Pages 541-544
Background: Thrombotic thrombocytopenic purpura, a life-threatening multisystem disease, has been infrequently associated with use of ticlopidine, a platelet anti-aggregating agent.
Purpose: To review 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura.
Data Sources: Medical records, published case reports, and case reports submitted to the U.S. Food and Drug Administration.
Study Selection: Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified.
Data Synthesis: Ticlopidine had been prescribed for less than 1 month in 80% of the patients, and normal platelet counts had been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients. Mortality rates were higher among patients who were not treated with plasmapheresis than among those who underwent plasmapheresis (50% compared with 24%; P < 0.05).
Conclusions: Ticlopidine use may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of initiation of therapy. The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despite close monitoring of platelet counts.
Ticlopidine, an antiplatelet agent, has rarely been associated with thrombotic thrombocytopenic purpura [6-14]. From the time when ticlopidine was first marketed (in October 1991) through March 1995, the U.S. Food and Drug Administration received reports of 25 ticlopidine users who developed thrombotic thrombocytopenic purpura [7]. Ticlopidine is used for treatment of intermittent claudication; for prevention of thrombotic strokes; and, more recently, for patients with cardiac stents. Early clinical trials identified neutropenia with bone marrow aplasia as the most common serious side effect of ticlopidine (with an incidence of 2.4% in clinical trials), but instances of ticlopidine-associated thrombotic thrombocytopenic purpura have been infrequently described [8-14]. We describe clinical characteristics, time course until the onset of disease, response to treatment, and outcomes in 60 patients with ticlopidine-associated thrombotic thrombocytopenic purpura. BRIEF COMMUNICATION
Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine: A Review of 60 Cases
Thrombotic thrombocytopenic purpura is a life-threatening multisystem disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic changes, progressive renal failure, and fever [1, 2]. Its frequency is estimated to be only 3.7 cases per year per 1 million persons, with mortality rates ranging from 10% to 20% [3-5]. Although the cause of thrombotic thrombocytopenic purpura is unknown, many drugs, including penicillin, antineoplastic chemotherapy agents, and oral contraceptives, have been associated with the syndrome [6].
Methods
Top
Methods
Discussion
Author & Article Info
References
Cases of ticlopidine-associated thrombotic thrombocytopenic purpura were identified from five sources: 1) reports obtained from MedWatch, the U.S. Food and Drug Administration's spontaneous reporting system [n = 36]; 2) previously published case reports (n = 11) [8-14]; 3) case summaries given to us after an informal survey of 20 hematologists on ticlopidine-associated thrombotic thrombocytopenic purpura [n = 6]; 4) cases reported to us from physicians affiliated with a large therapeutic plasmapheresis program (HemaCare, Inc., Sherman Oaks, California [n = 4]); and 5) medical records of patients with thrombotic thrombocytopenic purpura who were seen by physicians at Northwestern Memorial Hospital, Chicago, Illinois (n = 3). The case definition for ticlopidine-associated thrombotic thrombocytopenic purpura included use of ticlopidine and development of thrombotic thrombocytopenic purpura as measured by the scoring system proposed by Rose and Eldor [5]. The scoring system comprises four categories: platelet count (x109/L), hemoglobin level (g/L), serum creatinine level (micromol/L), and neurologic changes. Each category is assigned a score of 0, 1, or 2 on the basis of set criteria; a total combined category score of 4 or more indicates a diagnosis of thrombotic thrombocytopenic purpura.
Data Synthesis
We identified 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura (Table 1). Almost two thirds of the patients were older than 60 years of age, half were male, and 72% had received ticlopidine for stroke prevention. Normal platelet counts within 2 weeks of onset of thrombotic thrombocytopenic purpura were documented in two thirds of patients for whom platelet counts before disease onset were available. Ticlopidine therapy was stopped in all patients upon diagnosis of thrombotic thrombocytopenic purpura. The most common concomitant medications were aspirin (22%), metoprolol (12%), diltiazem (15%), hydrochlorothiazide (7%), and nitroglycerin (7%). In almost all cases, ticlopidine was the only new drug prescribed in the month preceding the onset of thrombotic thrombocytopenic purpura. Ticlopidine had been prescribed for less than 2 weeks for 15% of patients and less than 1 month for 80% of patients.
|
In all patients, thrombotic thrombocytopenic purpura was manifested by thrombocytopenia, anemia, neurologic changes, or renal dysfunction: Platelet counts were less than 20 x 109/L in two thirds of patients; hemoglobin levels were less than 90 g/L in 28% of patients; neurologic changes, including focal deficits, convulsions, or coma, were seen in 75% of patients; and renal insufficiency with a serum creatinine level greater than 221 µmol/L was seen in 25% of patients. Plasmapheresis was performed in 63% of patients; the rate was significantly higher among patients who were younger than 60 years of age (81% for persons <60 years of age and 54% for persons 
60 years of age; P = 0.028).
Overall, the survival rate for patients with thrombotic thrombocytopenic purpura was 67%. Although no patient has had relapse, none have been rechallenged with ticlopidine. Plasmapheresis was the most important predictor of death: The mortality rate was 24% among patients who underwent plasmapheresis and 50% among patients who did not undergo this procedure (P = 0.049).
Discussion
|
|---|
|
TopMethodsDiscussionAuthor & Article InfoReferences |
|---|
Undergoing plasma exchange is important for patients with thrombotic thrombocytopenic purpura. In a randomized trial, Rock and colleagues [3] reported a mortality rate of 22% among persons who underwent plasma exchange compared with a mortality rate of 83% among patients who underwent plasma infusion [3]. Similarly, we found a mortality rate of 24% among patients who underwent plasma exchange compared with a mortality rate of 50% among patients who did not undergo this procedure.
Our description of cases of ticlopidine-associated thrombotic thrombocytopenic purpura is limited because we used a clinical definition of the syndrome. Most of our patients had a score of 4 or more according to the scoring system of Rose and Eldor; four patients had a score of 3 and a diagnosis of thrombotic thrombocytopenic purpura made by an attending hematologist [5]. Patients were not directly seen by us, and patient information was provided by case reports (rather than hospital records) that often did not include complete records of laboratory values and clinical findings. These factors prevented us from obtaining complete clinical information on all patients.
The mechanism by which ticlopidine induces the clinical manifestations of thrombotic thrombocytopenic purpura is unclear. Ticlopidine, a thienopyridine compound, alters platelet function by inhibiting the binding of adenosine 5' diphosphate to its adenylyl cyclase-coupled receptor site [15, 16]. The drug decreases clottable fibrinogen but not fibrinogen antigen [17] and decreases fibronectin [18]. A metabolite of ticlopidine rather than the parent compound is thought to be responsible for these actions [19]. It is paradoxical that a drug that inhibits platelet function is incriminated in a disorder that is manifested by platelet thrombi. This suggests that in patients who develop thrombotic thrombocytopenic purpura, a metabolite of ticlopidine with an activity very different from that of the parent compound may produce this disorder.
Most physicians are aware that neutropenia, hepatic cholestasis, and thrombocytopenia are adverse effects of ticlopidine [6, 20]. One review of an estimated 10 million patient-years of ticlopidine treatment [7] identified 645 cases of aplastic anemia, bone marrow suppression, pancytopenia, and agranulocytosis, of which 102 (16%) were coded as fatal. Because hematologic side effects of ticlopidine almost always occur within the first 3 months of therapy, the U.S. Food and Drug Administration issued advisory warnings when ticlopidine was approved, advising physicians to perform complete blood counts every 2 weeks for 12 weeks. However, compliance with this recommendation is unlikely to assist in early detection of thrombotic thrombocytopenic purpura. For most patients in our study, platelet counts were within normal limits 2 weeks before the onset of thrombotic thrombocytopenic purpura.
Our study raises concern about the potential for underdiagnosis and subsequent undertreatment of ticlopidine-associated thrombotic thrombocytopenic purpura. After cardiac stent placement or after saphenous vein grafting for treatment of peripheral vascular disease, patients usually receive ticlopidine for 2 to 4 weeks. Given this short period, many cardiologists do not monitor complete blood counts; consequently, thrombocytopenia associated with thrombotic thrombocytopenic purpura may go unrecognized. In our study, 12 patients developed thrombotic thrombocytopenic purpura after receiving ticlopidine for 3 weeks or less after placement of cardiac stents; 3 of these patients died. For older patients who receive ticlopidine to prevent stroke, the onset of thrombotic thrombocytopenic purpura may be insidious, with symptoms of altered neurologic function that mimic a stroke. Physicians may attribute these changes to cerebrovascular disease and may not institute plasmapheresis in a timely manner. In our study, only 60% of patients with thrombotic thrombocytopenic purpura who received ticlopidine for stroke prevention were treated with plasmapheresis. In some patients who survived, plasmapheresis was withheld because of good patient response to fresh frozen plasma, platelets, or steroids. In several of the patients who died, thrombotic thrombocytopenic purpura was diagnosed only in retrospect.
Ticlopidine is being used more frequently for prevention of stroke and clot formation after cardiac stent placement and as a treatment for intermittent claudication. The large number of cases of ticlopidine-associated thrombotic thrombocytopenic purpura that we have reviewed suggests that caution should be taken in prescribing this compound. Patients selected for ticlopidine therapy should be fully informed about the serious hematologic toxicity, including neutropenia and thrombotic thrombocytopenic purpura, that can develop within the first few weeks of therapy.
Drs. Rozenberg-Ben-Dror and Kwaan: Chicago Veterans Affairs HealthCare System-Lakeside Division, 333 East Huron, Chicago, IL 60611.
Dr. Yarnold: Time Life Building, #300, 303 East Ohio, Chicago, IL 60611.
Dr. Green: Rehabilitation Institute of Chicago, #1407, 345 East Superior, Chicago, IL 60611.
Author and Article Information
|
|---|
|
TopMethodsDiscussionAuthor & Article InfoReferences |
|---|
References
|
|---|
|
TopMethodsDiscussionAuthor & Article InfoReferences |
|---|
1. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991; 325:398-403.
2. Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura. Blood Rev. 1993; 7:94-103.
3. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991; 325:393-7.
4. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968-1991. Am J Hematol. 1995; 50:84-90.
5. Rose M, Eldor A. High incidence of relapse in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med. 1987; 83:437-44.
6. Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997; 34:140-7.
7. Wysowski DK, Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users [Letter]. JAMA. 1996; 276:952.
8. Kovacs MJ, Soong PY, Chin-Hee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother. 1993; 27:1060-1.
9. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991; 337:774-6.
10. Capra R, Marciano N, Fieni F, Capucci M, Ferremi P, Orlandini A. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: case report. Acta Neurol Belg. 1992; 92:83-7.
11. Kodama K, Nomura T, Yasui K, Matsuo T. [Thrombotic thrombocytopenia purpura after administration of ticlopidine.] Rinsho Ketsueki. 1996; 37:1334-6.
12. Ariyoshi K, Shinohara K, Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis [Letter]. Am J Hematol. 1997; 54:175-6.
13. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura [Letter]. N Engl J Med. 1997; 337:1245.
14. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G. Thrombotic thrombocytopenic purpura associated with ticlopidine [Letter]. Stroke. 1992; 23:922-3.
15. Gachet C, Stierle A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol. 1990; 40:229-38.
16. Savi P, Laplace MC, Maffand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994; 269:772-7.
17. de Maat MP, Arnold AE, van Buuren S, Wilson JH, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost. 1996; 76:166-70.
18. Piovella F, Ricetti MM, Samaden A, Custodi P, Montecchio GP. Ticlopidine normalized abnormally high platelet fibronectin levels in retinopathic diabetics. Blood. 1985; 66:311.
19. Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: review. Semin Thromb Hemost. 1989; 15:159-66.
20. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989; 321:501-7.
This article has been cited by other articles:
|
|
 |
|
  G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Bennett, B. Kim, A. Zakarija, N. Bandarenko, D. K. Pandey, C. G. Buffie, J. M. McKoy, A. D. Tevar, J. F. Cursio, P. R. Yarnold, et al. Two Mechanistic Pathways for Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura: A Report From the SERF-TTP Research Group and the RADAR Project J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1138 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Bennett, J. R. Nebeker, P. R. Yarnold, C. C. Tigue, D. A. Dorr, J. M. McKoy, B. J. Edwards, J. F. Hurdle, D. P. West, D. T. Lau, et al. Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers Arch Intern Med, May 28, 2007; 167(10): 1041 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Aronow Use of Antiplatelet Drugs in Secondary Prevention in Older Persons With Atherothrombotic Disease J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. George Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura J Intensive Care Med, March 1, 2007; 22(2): 82 - 91. [Abstract] [PDF]
|
|
|
|
 |
|
 D. G. Jamieson, A. Parekh, and M. D. Ezekowitz Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 153 - 161. [Abstract] [PDF]
|
|
|
|
|
|
D. K. Wysowski and L. Swartz Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions Arch Intern Med, June 27, 2005; 165(12): 1363 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Bennett, J. R. Nebeker, E. A. Lyons, M. H. Samore, M. D. Feldman, J. M. McKoy, K. R. Carson, S. M. Belknap, S. M. Trifilio, G. T. Schumock, et al. The Research on Adverse Drug Events and Reports (RADAR) Project JAMA, May 4, 2005; 293(17): 2131 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tran and S. S. Anand Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease JAMA, October 20, 2004; 292(15): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zakarija, N. Bandarenko, D. K. Pandey, A. Auerbach, D. W. Raisch, B. Kim, H. C. Kwaan, J. M. McKoy, B. P. Schmitt, C. J. Davidson, et al. Clopidogrel-Associated TTP: An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration Stroke, February 1, 2004; 35(2): 533 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Ladewski, S. M. Belknap, J. R. Nebeker, O. Sartor, E. A. Lyons, T. C. Kuzel, M. S. Tallman, D. W. Raisch, A. R. Auerbach, G. T. Schumock, et al. Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project J. Clin. Oncol., October 15, 2003; 21(20): 3859 - 3866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.B. Goldstein, D.B. Matchar, J. Hoff-Lindquist, G.P. Samsa, and R.D. Horner VA Stroke Study: Neurologist care is associated with increased testing but improved outcomes Neurology, September 23, 2003; 61(6): 792 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Chang and T. Naqvi Thrombotic Thrombocytopenic Purpura Associated with Bone Marrow Metastasis and Secondary Myelofibrosis in Cancer Oncologist, August 1, 2003; 8(4): 375 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick, D. Richardson, M. Kelly, S. Ruland, E. Hung, Y. Harris, S. Kittner, and S. Leurgans Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients: A Randomized Trial JAMA, June 11, 2003; 289(22): 2947 - 2957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Jaff Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options Angiology, November 1, 2002; 53(6): 627 - 633. [Abstract] [PDF]
|
|
|
|
|
|
R. F. Spiera, R. S. Berman, A. J. Werner, and H. Spiera Ticlopidine-Induced Lupus: A Report of 4 Cases Arch Intern Med, October 28, 2002; 162(19): 2240 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Ahmed, R K Siddiqui, A K Siddiqui, S A Zaidi, and J Cervia HIV associated thrombotic microangiopathy Postgrad. Med. J., September 1, 2002; 78(923): 520 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lee, Y. Kim, J. Lim, M. Kim, E. J. Lee, A. Lee, K. Y. Lee, C. S. Kang, S.-Y. Kim, K. Han, et al. Rapid, Sensitive Diagnosis of Hemolytic Anemia Using Antihemoglobin Antibody in Hypotonic Solution Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 37 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. George, J. E. Sadler, and B. Lammle Platelets: Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2002; 2002(1): 315 - 334. [Abstract] [Full Text]
|
|
|
|
|
|
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]
|
|
|
|
|
|
C. F. Persoz, F. Cornella, P. Kaeser, and T. Rochat Ticlopidine-Induced Interstitial Pulmonary Disease : A Case Report Chest, June 1, 2001; 119(6): 1963 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119(1_suppl): 283S - 299S. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Chest, January 1, 2001; 119(1_suppl): 300S - 320S. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119(1_suppl): 321S - 336S. [Full Text] [PDF]
|
|
|
|
 |
|
 The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease Eur. Heart J., December 2, 2000; 21(24): 2033 - 2041. [Abstract] [PDF]
|
|
|
|
 |
|
 F. L. Paradiso-Hardy, C. M. Angelo, K. L. Lanctot, and E. A. Cohen Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality Can. Med. Assoc. J., November 1, 2000; 163(11): 1441 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Salliere, K. B. Kassler-Taub, A. E. Trontell, P. K. Honig, J. Z. Brooker, R. T.F. Cheung, M. R. Goldstein, C. L. Bennett, J. M. Connors, J. L. Moake, et al. Clopidogrel and Thrombotic Thrombocytopenic Purpura N. Engl. J. Med., October 19, 2000; 343(16): 1191 - 1194. [Full Text]
|
|
|
|
|
|
J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr Coronary Artery Stents JAMA, October 11, 2000; 284(14): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kaplan, A. Kaplan, K. Marcoe, and L. R. Sauvage Ticlopidine, Alka-Seltzer(R), or a Combination of Citric Acid With Aspirin: Effects on Platelet Aggregation in Individuals With an Insufficient Response to Aspirin Alone Clinical and Applied Thrombosis/Hemostasis, October 1, 2000; 6(4): 222 - 225. [Abstract] [PDF]
|
|
|
|
 |
|
 M. R. Sannes and K. S. Modi Acute renal failure and thrombocytopenia after ticlopidine--not necessarily thrombotic thrombocytopenic purpura Nephrol. Dial. Transplant., July 1, 2000; 15(7): 1076 - 1079. [Full Text] [PDF]
|
|
|
|
 |
|
 S L Allford and S J Machin Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura J. Clin. Pathol., July 1, 2000; 53(7): 497 - 501. [Full Text] [PDF]
|
|
|
|
 |
|
 P. H.N. Oomen, J. E. Tulleken, and J. G. Zijlstra Hemolytic Uremic Syndrome in a Patient Treated with Clopidogrel Ann Intern Med, June 20, 2000; 132(12): 1006 - 1006. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bennett, J. M. Connors, J. M. Carwile, J. L. Moake, W. R. Bell, S. R. Tarantolo, L. J. McCarthy, R. Sarode, A. J. Hatfield, M. D. Feldman, et al. Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel N. Engl. J. Med., June 15, 2000; 342(24): 1773 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Sacco and M. S. Elkind Update on Antiplatelet Therapy for Stroke Prevention Arch Intern Med, June 12, 2000; 160(11): 1579 - 1582. [Full Text] [PDF]
|
|
|
|
|
|
H.-M. Tsai, L. Rice, R. Sarode, T. W. Chow, and J. L. Moake Antibody Inhibitors to von Willebrand Factor Metalloproteinase and Increased Binding of von Willebrand Factor to Platelets in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura Ann Intern Med, May 16, 2000; 132(10): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Moy, J. C. Wang, G. D. Raffel, and J. P. Marcoux II Hemolytic Uremic Syndrome Associated With Clopidogrel: A Case Report Arch Intern Med, May 8, 2000; 160(9): 1370 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill, P. Serruys, M. Knudtson, G.-A. van Es, G. C. Timmis, C. van der Zwaan, J. Kleiman, J. Gong, E. B. Roecker, R. Dreiling, et al. Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization N. Engl. J. Med., May 4, 2000; 342(18): 1316 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Muller, H. J. Buttner, J. Petersen, and H. Roskamm A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary-Artery Stents Circulation, February 15, 2000; 101(6): 590 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Mishkel, F. V. Aguirre, R. W. Ligon, K. J. Rocha-Singh, C. L. Lucore, and for Prairie Cardiovascular Consultants Ltd Clopidogrel as adjunctive antiplatelet therapy during coronary stenting J. Am. Coll. Cardiol., December 1, 1999; 34(7): 1884 - 1890. [ |
Article
